During the 2005 Association for Research in Vision and
Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, FL from May
1-5, Regeneron will present clinical data in a poster entitled "A
double-masked, placebo-controlled, dose-escalating phase 1 study of
intravenous VEGF Trap in patients with neovascular age-related macular
degeneration: evaluation of safety, tolerability, visual acuity, and
ocular coherence tomography (OCT).
Regeneron also announced that it has completed small pilot studies
in healthy volunteers examining the effects of the IL-1 Trap on a
systemic marker of inflammation.regeneron.
The report is supplemented with 59 tables and 8 figures.

sclerosis stuttering

digestive hemophilia

Regeneron does not
undertake any obligation to update publicly any forward-looking
statement, whether as a result of new information, future events, or
otherwise unless required by law.researchandmarkets .
For more information visit
http://www.

hypertension spirochetal

(Nasdaq: REGN) announced today that data from
clinical and pre-clinical studies of the VEGF and IL-1 Traps will be
presented at three upcoming medical conferences in May and June. Jakob Dupont, a
medical oncologist at Memorial Sloan-Kettering Cancer Center, will
present a poster titled "Safety and pharmacokinetics of intravenous
VEGF Trap in a phase 1 clinical trial of patients with advanced solid
tumors.com

neurological degeneration

Pharmaceutical Writers/Business Editors/Health/Medical
Writers/Biotech Writers/Health Editors/Medical Editors

DUBLIN, Ireland ----Research and
Markets (http://www.com/reports/c1364) has
announced the addition of Neuroprotection - Drugs, Markets and
Companies to their offering
This report describes the role of neuroprotection in acute
disorders such as stroke and injuries of the nervous system as well as
in chronic diseases such as neurodegenerative disorders because many
of the underlying mechanisms of damage to neural tissues are similar
in all these conditions and several products are used in more than one
disorder . Although
anesthetics such as propofol are neuroprotective as well,
neuroprotection during surgery and anesthesia is discussed with the
aim of preventing and treating complications that result in CNS
damage.
The report contains a profile of 109 companies that have a
neuroprotective product or products. Some of the products in
development at academic institutions that do not have a commercial
sponsor are also included. Clinical trials of various neuroprotective agents are described
and failures of trials in stroke and head injury are analyzed with
suggestions for improving the selection of drugs and design of trials.

connective digestive

Y.
Presentations will include data in eye diseases, oncology and
inflammatory diseases. By that
time neuroprotection will be an established part of the neurological
practice and measures will be available to achieve this effectively.

hypertension spina

The oral
presentation will include data from a phase 2 study in patients with
CIAS1-Associated Periodic Syndrome (CAPS), which was funded in part by
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases, part of the National Institutes of Health.

blindness amyotrophic

Additional Information about Regeneron and recent news releases
are available on Regeneron's Worldwide Web Home Page at
www.

inflammatory celiac

" This trial was conducted under
Regeneron 's collaboration agreement with the sanofi-aventis Group for
eye diseases through systemic delivery systems, such as intravenous
infusions. The Company plans to submit the
results of these studies for presentation in an abstract at a
cardiovascular conference later this year and for publication in a
peer-reviewed medical journal. Some of these
products are approved for other indications but are known to have a
neuroprotective effect. With the approval of new products and takeover
of markets for obsolete symptomatic therapies, the neuroprotection
market value will rise $11.

neurological inflammatory

" Regeneron and sanofi-aventis are also collaborating on the
development and commercialization of the VEGF Trap in oncology.

This news release discusses historical information and includes
forward-looking statements about Regeneron and its products, programs,
finances, and business, all of which involve a number of risks and
uncertainties, such as risks associated with preclinical and clinical
development of drugs and biologics, determinations by regulatory and
administrative governmental authorities , competitive factors,
technological developments, the availability and cost of capital, the
costs of developing, producing, and selling products, the potential
for any collaboration agreement to be canceled or to terminate without
any product success, and other material risks.
Pathomechanisms of diseases are described with steps at which
neuroprotective therapies are directed.

sensitivity blindness

hypertension tourette

----Regeneron
Pharmaceuticals, Inc.

macular celiac

6 billion in all these areas.

hydrocephalus hypertension

Also at ARVO, Regeneron scientists will present eight posters
describing the results of pre-clinical research on the use of the VEGF
Trap to treat multiple eye diseases. Regeneron has therapeutic candidates in
clinical trials for the potential treatment of cancer and eye
diseases, rheumatoid arthritis and other inflammatory conditions and
asthma and allergies and has preclinical programs in other diseases
and disorders.

hemophilia spina

Regeneron Pharmaceuticals to Present Data from VEGF Trap and IL-1 Trap Studies

com/reports/c1364

lateral sclerosis

Market analysis shows that products currently used that have a
neuroprotective effect have a market value of 5.

hydrocephalus intestinal

At the 2005 American Society of Oncology (ASCO) Annual Meeting
taking place in Orlando, FL from May 13-17, Dr.

Research and Markets: With Approval Of New Products And Takeover Of Markets For Obsolete Symptomatic Therapies Neuroprotection Market Value Will Rise $11.5 Bi

intestinal spirochetal

About Regeneron

Regeneron is a biopharmaceutical company that discovers, develops,
and intends to commercialize therapeutic medicines for the treatment
of serious medical conditions.

inflammatory degeneration

Regeneron is independently
developing the VEGF Trap in eye diseases utilizing local delivery
systems, such as intraocular injections.

hydrocephalus spina

Although an up-to-date search of the
literature was performed and selected 500 references are included, a
considerable amount of information has not been published anywhere
else.1 billion out of a CNS
market value of $34.researchandmarkets.

inflammatory dystrophies

lateral spina

stuttering spina

Diseases covered include
cerebrovascular disorders, traumatic brain injury , spinal cord injury,
Alzheimer's disease, Parkinson's disease, Huntington's disease,
amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and
ischemic optic neuropathy as well as retinal degeneration.5 billion by the year 2010 when it will
constitute a major and important component of the CNS market.

bifida sclerosis

Business Editors/Health/Medical Writers
BIOWIRE2K

TARRYTOWN, N.

inflammatory demyelinating

During the Annual European Congress of Rheumatology in Vienna from
June 8-11, sponsored by the European League Against Rheumatism
(EULAR), data will be presented on the IL-1 Trap. A more complete
description of these risks can be found in Regeneron's filings with
the United States Securities and Exchange Commission, including its
Form 10-K for the year ended December 31, 2004. Over 300 products have been investigated for neuroprotective
effects including those from the categories of free radical
scavengers, anti-excitotoxic agents, apoptosis (programmed cell death)
inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion
chelators, ion channel modulators and gene therapy. Some of the agents
are old established pharmaceuticals whereas others are new
biotechnology products .